Paroxetine (Brisdelle): The Definitive Guide

What is low-dose paroxetine for menopause?

Brisdelle is a US prescription product containing 7.5 mg paroxetine, a selective serotonin reuptake inhibitor or SSRI. It is approved for moderate to severe vasomotor symptoms associated with menopause: hot flashes and night sweats. It contains no estrogen. This specific product is not indicated to treat depression, anxiety disorders or other psychiatric conditions. [1], [2]

The low-dose product and higher-dose psychiatric paroxetine products are different treatment contexts. They may share an active medicine but do not share every indication, formulation or amount. A request for hot-flash relief is not evidence that symptoms are psychological. Conversely, someone needing psychiatric treatment should not assume the Brisdelle amount provides it. The prescriber should identify each clinical goal. [1], [2]

The usual Brisdelle amount is one 7.5 mg capsule at bedtime. Low dose does not mean no interaction or warning: the label includes suicidal-thought/behavior precautions, serotonin syndrome, bleeding, sodium, sexual-function and other issues. Tamoxifen requires particular review because paroxetine can reduce its active-metabolite exposure. The medication review matters as much as the capsule count. [1], [2]

Which product and schedule were studied?

Ordinary labeled use is one 7.5 mg capsule daily at bedtime, with or without food. It is continuous daily treatment, not a sequential hormone cycle or as-needed rescue. The reviewed Brisdelle label does not provide a higher-dose VMS titration ladder. A psychiatric indication requires the appropriate psychiatric product and plan, while MAOI separation is an independent safety requirement. [1], [2]

What can it help, and what is outside its indication?

The main treatment goal is reducing moderate to severe hot-flash frequency and severity. It can be considered as one nonhormonal option in an appropriate clinical plan. The actual choice depends on the symptoms, other medicines, psychiatric history, unwanted effects and local product availability. It should not be substituted for systemic estrogen simply by comparing milligrams. [1], [2], [9]

Nighttime awakenings attributed to vasomotor symptoms were reduced in a pooled trial analysis. At four weeks, awakenings fell by 39% with 7.5 mg paroxetine and 28% with placebo; sleep duration rose by 31 versus 16 minutes. Those are group results in postmenopausal trial participants, not a guarantee of sedation or treatment of every insomnia cause. Sleep-onset latency did not differ significantly between groups. [4]

A pooled weight/sexual-function analysis found no clinically meaningful adverse group changes over 12–24 weeks. That observation can inform the discussion but cannot guarantee no weight change, libido loss or delayed orgasm for a particular person. The current label explicitly warns that SSRIs including Brisdelle can cause sexual dysfunction and asks clinicians to assess it before and during treatment. Both findings belong on the page. [1], [5]

Dryness, painful sex, urinary symptoms, bone health and clinically significant psychiatric symptoms require their own assessment. A public user can find hot flashes improved while vaginal symptoms remain; that is not a treatment failure for an outcome the product does not claim to address. The nonhormonal options guide helps separate symptom goals and different approaches. [1], [7], [9]

How does an SSRI affect hot flashes?

Paroxetine inhibits serotonin reuptake. Serotonin signaling is relevant to temperature regulation, but the US label says the exact mechanism by which Brisdelle treats menopausal vasomotor symptoms is unknown. A simplified neurotransmitter explanation should not be presented as a proven step-by-step correction of a person’s brain chemistry. [1], [2]

Its SSRI action also helps explain interactions. Combining multiple serotonergic agents can increase serotonin-syndrome risk, and inhibiting CYP2D6 can affect other medicines. The hot-flash indication does not remove those pharmacological effects. A small capsule amount cannot be treated as interaction-free merely because it is below common psychiatric amounts. [1], [2]

Brisdelle does not deliver estrogen or a progestogen. It cannot be assumed to protect the uterine lining during a separate systemic estrogen prescription or to provide estrogen’s other tissue-related effects. Blood hormone targets do not measure the hot-flash response; actual episode burden, daily function and tolerability are more useful observations. [1], [9]

How much benefit did the trials show?

The current US label describes efficacy in two phase 3 placebo-controlled trials with an analyzed population of 1,174 postmenopausal women. They entered with at least seven to eight moderate/severe daily episodes, or at least 50 weekly. The original abstract reports 591 randomized to paroxetine and 593 to placebo; those randomized denominators differ from the analyzed label population. Do not silently label all of these as the same count. [1], [3]

At week 12 in trial 1, the median daily-frequency reduction was 5.9 episodes with Brisdelle and 5.0 with placebo, a median difference of 0.9. In trial 2, reductions were 5.6 and 3.9, a difference of 1.7. These are median changes, not the adjusted means used by some neurokinin trials. Both placebo groups improved; the comparative benefit is smaller than the total change from baseline. [1]

The trial 1 week-12 severity comparison was not statistically significant in the label table; the original abstract says three of four primary endpoints were met in the 12-week trial, versus all four in the 24-week trial. A statement that every endpoint was met would overstate the evidence. Frequency, severity, timepoint and analysis need to stay attached to the result. [1], [3]

At 24 weeks in trial 2, 48% with Brisdelle and 36% with placebo achieved at least a 50% reduction in episode frequency. That responder definition is a trial threshold, not a guarantee that the remaining users had no benefit or that everyone should continue until that week. Review meaningful benefit and unwanted effects in the actual treatment plan. [1]

The sleep and weight/sexual-function publications analyze the same underlying pivotal program. They add useful measured outcomes, but are not independent replications that can be counted as several new efficacy trials. Follow-up lasted 12–24 weeks, with selected participants and important exclusions. Longer real-world experience and current warnings remain relevant when judging individual tolerability. [3], [4], [5]

No head-to-head superiority is inferred against fezolinetant, elinzanetant or gabapentin. Different studies used different populations, symptom baselines, statistical summaries and follow-up. NICE and NAMS also frame first-line treatment differently. Product authorization and a guideline’s preferred place in care are separate judgments. [8], [9]

Which changes deserve prompt help?

The current label includes a boxed warning about suicidal thoughts and behaviors and asks for monitoring of everyone receiving Brisdelle, especially early in treatment. The broader antidepressant evidence concerns young people with psychiatric disorders, while information in menopausal VMS is limited and trials excluded relevant psychiatric histories. That distinction does not remove the need to assess new suicidal thinking, abrupt severe mood deterioration or unusual behavior. Seek urgent help if safety is at risk. [1], [2]

Serotonin syndrome can be life-threatening. A concerning cluster can include agitation or confusion, fever/sweating, racing heartbeat, muscle rigidity or twitching, coordination problems and gastrointestinal symptoms. It can occur with other serotonergic medicines and also with Brisdelle alone. The label requires stopping implicated treatment and medical care when the syndrome occurs; do not interpret it as ordinary hot flashes or a necessary adjustment period. [1], [2]

Headache, nausea/vomiting and fatigue or malaise are common listed adverse reactions. Their timing and impact on daily activities matter. The label says some early symptoms became less frequent with time in trials, but it does not guarantee improvement or require someone to tolerate severe impairment. A new symptom cluster can have another cause and should be reviewed rather than assigned to menopause by default. [1]

Bleeding risk can increase with aspirin, NSAIDs, antiplatelet medicines and anticoagulants. Hyponatremia means low blood sodium and is more concerning with older age, diuretics or volume depletion. New confusion, marked weakness, unsteadiness or a seizure needs assessment. The label also names angle-closure glaucoma, mania/hypomania, seizure precautions and fracture observations. The prescriber reviews relevant history rather than ordering an identical test panel for everyone. [1], [2]

Sexual function deserves a direct question before and during treatment. SSRIs can reduce desire or delay/prevent orgasm even though the short-term low-dose pooled study did not show a significant adverse group change. A person’s unwanted change should not be dismissed because the average trial finding was reassuring. Record timing and other possible contributors for discussion. [1], [5]

Pregnancy, MAOIs, thioridazine, pimozide and relevant hypersensitivity are contraindication contexts in the reviewed US label. Low-dose VMS treatment does not make these combinations or conditions acceptable. If another paroxetine product or antidepressant is already used, tell the clinician before adding Brisdelle so duplication and switch requirements are assessed. [1], [2]

Why is tamoxifen especially important?

Paroxetine strongly inhibits CYP2D6. Tamoxifen relies on metabolism to active metabolites including endoxifen, and paroxetine can reduce their exposure. The current label says some outcome studies suggested reduced tamoxifen effectiveness while others did not demonstrate that risk, and recommends weighing benefit/risk and considering avoidance of concurrent use. This is not proof that every exposed patient’s cancer will recur, but it is a material treatment-planning issue. [1], [2]

When tamoxifen is used for treatment or prevention, coordinate the hot-flash choice with the oncology team and pharmacist. Do not stop tamoxifen to make Brisdelle easier to use. Other nonhormonal choices may be considered in a plan that accounts for each interaction and indication. A history of cancer and active tamoxifen use are distinct questions; the actual regimen matters. [1], [2], [9]

MAOIs require the labeled 14-day separation in both directions. Linezolid and intravenous methylene blue can be relevant even when given for an acute problem rather than depression. Other serotonergic agents, St. John’s wort, certain opioids and supplements belong in the review. A brand-name-only medication list can hide duplicate paroxetine or serotonin effects. [1], [2]

CYP2D6 inhibition affects more than tamoxifen. The label’s interaction tables and other medicines’ instructions guide the pharmacist, including heart-rhythm and other narrow-margin treatments. Keep the full list of prescriptions, nonprescription pain medicines and supplements current. Do not assume a low VMS amount removes the need to disclose a new medication. [1], [2]

What if a capsule is missed or the product changes?

The reviewed Brisdelle instructions specify one daily bedtime capsule with or without food; they do not provide a detailed missed-dose algorithm comparable to the neurokinin products. Follow the dispensed directions and ask the pharmacist what to do for the actual timing. Do not improvise extra capsules or a new amount to treat a breakthrough episode. Keep the actual last dose visible. [1], [2]

A change to a generic, different salt, extended-release tablet or psychiatric paroxetine product needs verification of the actual product and purpose. The 7.5 mg Brisdelle capsule contains paroxetine mesylate equivalent to 7.5 mg paroxetine base, with 9.69 mg salt mass. Those are two descriptions of one capsule, not two dosing options. A tablet fraction cannot be assumed equivalent from arithmetic alone. [1], [2]

Discuss refill gaps and stopping plans before the capsule supply runs out. Partial benefit or another medicine’s adverse effects may prompt a broader review rather than a higher paroxetine amount. A forum post about a different formulation cannot establish how to split this capsule or switch between products. [1], [2], [6]

How should the capsule and records be kept?

The US label gives storage at 20–25°C, with excursions permitted to 15–30°C, and protection from light and humidity. Keep the medication identifiable in its packaging and follow expiry directions. The current packager’s presentation can differ from an older FDA PDF’s pack details without changing the active ingredient; use the actual dispensed product. [1], [2]

Record the exact product, amount, bedtime use and start/stop dates alongside the symptom goal. List tamoxifen, other antidepressants, pain medicines and supplements explicitly. Notes about mood, sleep, sexual function and hot-flash interference can help review, but they cannot exclude serotonin syndrome, a psychiatric crisis or another serious adverse effect. [1], [2]

This protocol is for the reviewed US Brisdelle authorization. It does not establish approval of that brand/amount for VMS in every country, current stock or insurer coverage. NICE’s treatment position is a UK guideline judgment rather than a worldwide product license. Ask the local pharmacist and prescriber about the actual authorized product and access pathway. [1], [8], [9]

What do public accounts reveal about expectations?

A public 2025 discussion describes initial benefit followed by returning hot flashes and uncertainty about stopping a 7.5 mg capsule and trying alternatives. That is a selected experience, not a typical response timeline or proof that every SSRI loses effect. It shows why follow-up should distinguish early change, sustained benefit, actual use and the next treatment plan. [6]

A selected reply in another public discussion describes perceived hot-flash benefit while vaginal symptoms remained a reason for separate treatment. This helps explain the difference between a useful symptom-specific result and a complete menopause solution. It is not controlled evidence for combining cannabis, alcohol or other products with paroxetine. [7]

Improvement, returning symptoms and concerns about tolerability or access remain visible together. Public discussions cannot determine a safe dose, taper or oncology interaction. No satisfaction percentage, usernames or identifying details are reproduced. Bring the practical question, not a copied forum prescription, to the clinical review. [6], [7]

What should be monitored?

Before starting, review the complete medicine list, psychiatric history, bipolar risk, previous reactions, seizure/eye history and circumstances that increase bleeding or low-sodium risk. Ask specifically about tamoxifen and other antidepressants. This is not a one-size laboratory panel or a hormone target; it is product-specific suitability assessment. [1], [2]

During treatment, review hot-flash frequency/interference, sleep, actual daily function and unwanted effects. Ask about new mood or behavior changes early, and about sexual function even if it is not volunteered. The product’s VMS indication does not provide treatment for an emerging psychiatric disorder. A meaningful problem can justify earlier review rather than the next routine visit. [1], [2]

Testing depends on the actual risk or finding. The label gives particular attention to sodium-related symptoms and increased bleeding; people taking warfarin require careful INR monitoring. A lab or symptom record supports the clinical history but cannot diagnose serotonin syndrome or clear a dangerous interaction. Keep the underlying reports available. [1], [2]

Document start date, formulation, actual use and changes in any interacting medicines. If benefit is small or not sustained, discuss whether the treatment remains worthwhile and which goal still needs care. Do not transform a responder threshold from a trial into an obligation to tolerate troublesome symptoms. [1], [6]

What happens when treatment stops?

The low-dose pivotal program reported minimal acute discontinuation symptoms, and the pooled sleep paper describes stopping 7.5 mg without a required taper in those trials. Current postmarketing information nevertheless lists withdrawal syndrome among reports for this and other paroxetine products. These are compatible observations with different evidence settings; neither guarantees a symptom-free stop for every person. [1], [3], [4]

There is no universal capsule-splitting taper in this guide. Agree on a stopping or switching plan with the prescriber, especially when a psychiatric paroxetine product, another antidepressant or a different formulation is involved. The Brisdelle amount is not the same situation as higher-dose psychiatric treatment. A switch to an MAOI retains the at-least-14-day interval after Brisdelle stops. [1], [2]

Serotonin syndrome, a seizure, symptomatic hyponatremia or serious emergent mood concerns can require urgent assessment and product-specific stopping instructions. Do not delay needed care to finish a taper from a forum. For a planned stop without an urgent problem, record the last actual dose, symptoms and the replacement hot-flash plan. Separate vaginal, hormonal and cancer treatment decisions remain intact. [1], [2], [6]

How does it compare with other options?

NAMS 2023 recommends SSRIs/SNRIs among evidence-supported nonhormonal options for vasomotor symptoms. NICE NG23 says not routinely to offer SSRIs/SNRIs or clonidine as first-line treatment for VMS alone. These are named positions within different care contexts. Neither converts the US Brisdelle authorization into a universal first choice or proves that an approved product cannot help. [8], [9]

Fezolinetant and elinzanetant are neurokinin antagonists with different interactions and testing plans. Gabapentin represents another mechanism and another tolerability profile. Compare clinical goals, safety history, actual concurrent treatment and practical follow-up rather than capsule size or milligrams. Separate trial tables do not establish a head-to-head ranking. [1], [9]

If depression or anxiety needs treatment, choose a plan appropriate to that diagnosis and coordinate the hot-flash goal. If tamoxifen is used, its effectiveness and potential interactions are central. If vaginal symptoms or bone risk remain, they need separate care. A low-dose hot-flash product can be useful without being a complete menopause or psychiatric prescription. [1], [2], [9]

Common questions

Does using an SSRI mean the hot flashes are psychological?

No. Brisdelle has a specific US vasomotor-symptom indication supported by controlled trials. It is not estrogen, and its exact VMS mechanism remains unknown. The product is not indicated for psychiatric conditions at this amount. Each problem should be assessed on its own merits. [1], [2], [3] Coordinate any separate psychiatric need rather than assuming this symptom amount covers it. The trial indication and a mental-health diagnosis answer different clinical questions. See the clinical purpose. [1] [2]

Is it the same prescription as psychiatric Paxil?

It shares the active medicine paroxetine, but the 7.5 mg capsule, indication and evidence are specific. Other amounts and formulations have their own psychiatric labeling and stop instructions. Do not assume a tablet fraction or duplicate product is interchangeable. See protocols. [1], [2] Confirm the product, strength and clinical purpose whenever a prescription changes. Taking duplicate paroxetine products can create an unintended total exposure. See the product schedules. [1] [2]

Can I take it with tamoxifen?

This requires clinician/pharmacist and oncology review. Paroxetine inhibits CYP2D6 and can reduce active tamoxifen-metabolite exposure; the label recommends weighing the issue and considering avoidance. Do not stop tamoxifen yourself. A nonhormonal label does not remove an interaction. [1], [2], [9] Other hot-flash options can be considered within the coordinated plan. The interaction discussion should preserve effective cancer treatment rather than independently removing it. See the medication interactions. [1] [2]

Is sexual dysfunction impossible at 7.5 mg?

No. The short pooled study did not show a significant adverse group change, but current labeling warns of reduced libido and delayed or absent orgasm. Ask about individual changes before and during treatment. A reassuring average does not invalidate a person’s experience. [1], [5] The person’s baseline and change over time make the review more useful. The pooled analyses were short and cannot rule out every individual effect. See the safety precautions. [1] [5]

Does everyone need a slow taper?

No universal Brisdelle taper is established here. Low-dose trials reported minimal acute discontinuation symptoms and did not require tapering, while current postmarketing information includes withdrawal syndrome. Higher-dose/other formulations are different. Agree on a plan with the prescriber rather than splitting capsules or copying another product’s schedule. [1], [3], [4] A planned switch can introduce its own interaction and separation requirements. Keep the last actual dose and the new product’s instructions available to the prescriber. See the stopping considerations. [1] [3]

What should I do with severe new mood or neurological symptoms?

Seek prompt or urgent medical help according to severity, especially if suicidal thinking, confusion, seizure or a serotonin-syndrome cluster occurs. Do not wait out a forum adaptation period. The label’s safety instructions and actual interacting medicines guide assessment. See risks. [1], [2] Several symptoms together and the concurrent medicine list can change the urgency. A diary should support care rather than become a reason to postpone it. See the safety precautions. [1] [2]

Why do NICE and NAMS describe its place differently?

NAMS 2023 recommends SSRIs/SNRIs as evidence-supported nonhormonal options. NICE says not routinely to offer them as first-line treatment for VMS alone. Those are different care-context recommendations; neither erases the US Brisdelle authorization or makes it a universal preferred first choice. [8], [9] Discuss the recommendation within the actual local care setting. The most suitable choice also depends on interactions, other diagnoses and what symptom needs treatment. See the treatment comparisons. [8] [9]

Glossary

Terms used to read the product and evidence.

ALT

A liver-related enzyme measured in blood; an elevation needs clinical interpretation.

AST

An enzyme measured with other liver tests; it is not a symptom score.

Alkaline phosphatase

A blood-test enzyme used with other findings to assess liver or biliary problems.

Antagonist

A substance that blocks activity at a particular receptor.

Baseline

A measurement recorded before treatment begins.

Bilirubin

A pigment measured in blood; its elevation can accompany liver or biliary disease.

Boxed warning

A prominent US label warning about a serious risk.

CYP enzyme

An enzyme involved in medicine metabolism; inhibitors and inducers may alter exposure.

Cirrhosis

Advanced liver scarring; product restrictions may specifically name it.

Contraindication

A circumstance in which a product label says the medicine must not be used.

Drug-induced liver injury

Liver injury attributed to a medicine after assessment of other possible causes.

Endocrine therapy

Treatment affecting hormone production or action; cancer endocrine therapy is distinct from menopausal HRT.

Estrogen

A hormone used in some menopause treatments; these nonhormonal medicines do not replace it.

Hot flash

An episode of heat, often with flushing or sweating.

Hypothalamus

A brain region involved in temperature regulation and other bodily functions.

Inducer

A substance that increases enzyme activity, potentially reducing exposure to another medicine.

Inhibitor

A substance that reduces enzyme activity, potentially increasing exposure to another medicine.

Jaundice

Yellowing of skin or the whites of the eyes that needs assessment.

Least-squares mean

A model-adjusted average used in trial analyses, distinct from a simple raw average.

Median

The middle value in ordered data, different from the arithmetic mean.

Neurokinin receptor

A receptor responding to neurokinin signals; a drug may block a specified subtype.

Night sweat

Sweating episodes during sleep; a vasomotor episode is one possible cause.

Nonhormonal

A treatment that does not supply estrogen or progestogen; the term does not mean risk-free.

Off-label

Use outside the authorization for the exact product and jurisdiction.

Placebo

A comparison treatment without the trial medicine; its group can still improve.

Progestogen

A hormone-family treatment used for endometrial protection in many systemic estrogen regimens.

Randomized trial

A study assigning treatment groups by chance to help compare outcomes.

SSRI

A selective serotonin reuptake inhibitor; some specific products or amounts are used for hot flashes.

Serotonin

A chemical messenger affected by SSRIs and relevant to their interactions.

Tamoxifen

An endocrine medicine used in breast-cancer care; interacting treatments need review.

Upper limit of normal

The upper reference limit provided by the evaluating laboratory.

Vasomotor symptoms

Hot flashes and night sweats associated with menopause or a specifically assessed other cause.

How this guide was researched

We reviewed the full current DailyMed label, full FDA February 2025 PDF, original efficacy-trial abstract, full pooled sleep and weight/sexual-function analyses, current NICE NG23 and the full 2023 NAMS statement. The original efficacy paper was not accessed in full; detailed numerical efficacy comes from the complete label. Randomized and analyzed denominators, medians and modeled means remain distinct. [1]–[5], [8], [9]

The pooled publications are not counted as independent replications. Current warnings retain their place beside reassuring short-term findings. Protocol comes from the actual 7.5 mg product, without an invented conversion from another paroxetine formulation. Approval, guideline placement and local coverage are separate claims.

Selected public thread text was rechecked through search and supports qualitative reader questions only. No response rates, private education, Academy content or prescribing authority are inferred. Checked 2 October 2026.

Explore the sources